Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report)'s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $9.17 and traded as high as $10.93. Anavex Life Sciences shares last traded at $10.76, with a volume of 729,059 shares trading hands.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and set a $42.00 price target on shares of Anavex Life Sciences in a research note on Monday, April 7th. D. Boral Capital restated a "buy" rating and issued a $46.00 price target on shares of Anavex Life Sciences in a report on Monday, April 7th.
Get Our Latest Analysis on AVXL
Anavex Life Sciences Stock Down 0.5%
The company has a market capitalization of $950.00 million, a P/E ratio of -20.14 and a beta of 0.72. The business's 50-day moving average is $8.68 and its two-hundred day moving average is $9.17.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same quarter in the prior year, the business posted ($0.13) earnings per share. Analysts predict that Anavex Life Sciences Corp. will post -0.69 EPS for the current year.
Hedge Funds Weigh In On Anavex Life Sciences
Several hedge funds have recently bought and sold shares of AVXL. Vermillion Wealth Management Inc. purchased a new position in Anavex Life Sciences during the fourth quarter valued at approximately $34,000. Tower Research Capital LLC TRC grew its stake in Anavex Life Sciences by 102.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 1,708 shares in the last quarter. E Fund Management Co. Ltd. purchased a new position in Anavex Life Sciences during the first quarter valued at approximately $102,000. Prudential Financial Inc. purchased a new position in Anavex Life Sciences during the fourth quarter valued at approximately $109,000. Finally, 180 Wealth Advisors LLC purchased a new position in Anavex Life Sciences in the 1st quarter worth approximately $121,000. Hedge funds and other institutional investors own 31.55% of the company's stock.
About Anavex Life Sciences
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
See Also
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
